Johnson and Johnson Shares Outstanding Data and Investor Insights

Johnson and Johnson's shares outstanding have fluctuated over the years, with a significant increase in the early 2000s.

The company's shares outstanding peaked at 3.4 billion in 2002.

One of the key factors that contributed to this growth was the company's strong financial performance and strategic acquisitions.

The number of shares outstanding remained relatively stable from 2002 to 2008, with a slight decline to 3.2 billion in 2008.

Johnson and Johnson's financial data paints a picture of a company with significant revenue and profits. Revenue for the last 12 months was a staggering $88.82 billion.

Their net income available to common shareholders was $14.68 billion, which is a substantial amount of money.

The company's gross margin is a respectable 69.07%, indicating that they are able to keep a significant portion of their revenue as profit.

Here is a breakdown of Johnson and Johnson's margins:

Johnson & Johnson's balance sheet provides a snapshot of the company's financial health. The company has a significant amount of debt, with $35.75 billion in total debt.

The company's cash and cash equivalents stand at $20.30 billion. This is a substantial amount of liquid assets that can be used to meet short-term financial obligations.

Johnson & Johnson's net cash position is -$15.45 billion, which is a negative figure indicating that the company's debt exceeds its cash and cash equivalents. This translates to a net cash per share of -$6.42.

The company's equity, also known as book value, is $70.16 billion. This value represents the company's net worth after deducting liabilities from assets.

Here is a summary of Johnson & Johnson's balance sheet:

Johnson & Johnson's balance sheet highlights the company's significant debt and negative net cash position, which may be a concern for investors.

The income statement is a crucial part of a company's financial data, providing a snapshot of its revenue and expenses over a specific period.

Let's take a look at Johnson & Johnson's (JNJ) income statement. In the last 12 months, JNJ had revenue of $88.82 billion.

Revenue per share was $36.42, which is a significant amount considering the company's market value. JNJ's gross profit was $61.35 billion, accounting for 69.07% of its revenue.

Here's a breakdown of JNJ's income statement:

JNJ's operating income was $21.25 billion, while its net income was $14.07 billion. The company's earnings per share (EPS) was $5.79, indicating a decent return on investment for shareholders.

Johnson & Johnson's Common Shares Outstanding amounts to 2.4B USD as of December 29, 2024.

The company's Common Shares Outstanding growth was 0% over the last year. This means that the number of shares outstanding remained the same, without any increase or decrease.

The average annual Common Shares Outstanding growth rates for Johnson & Johnson have been -3% over the past three years, indicating a consistent decline in the number of shares outstanding over this period.

Stock splits are a crucial aspect of a company's history, and understanding them can be helpful for investors.

The last stock split for this company was on June 13, 2001.

It was a forward split with a specific ratio that affected the number of shares. The split ratio was 2:1, which means that for every one share an investor had, they received one additional share.

This type of split is known as a forward split, which is a common way for companies to adjust their share prices.

A forward split increases the number of shares outstanding, which can make the stock more accessible to individual investors.

Here's a brief summary of the last stock split:

Let's take a look at the short selling information. The latest short interest is 16.46 million shares.

This is a significant number, but to put it into perspective, it's only 0.68% of the outstanding shares that have been sold short. In other words, most investors are still holding onto their shares.

The short interest has actually decreased from the previous month, when it was 18.54 million shares. This could be a sign that some investors are becoming more bullish on the stock.

Here's a snapshot of the current short selling information:

The short ratio, also known as the days to cover, is 1.94. This means that it would take approximately two weeks for all the short sellers to cover their positions.

Johnson and Johnson's market capitalization has consistently been one of the highest among pharmaceutical companies, reaching over $1 trillion in 2022.

The company's strong brand portfolio, including iconic brands like Band-Aid and Tylenol, has contributed to its success.

Johnson and Johnson's diversified business segments, including pharmaceuticals, medical devices, and consumer products, have helped the company stay afloat during economic downturns.

In 2020, the company generated $82.06 billion in revenue, with a significant portion coming from its pharmaceutical segment.

Johnson and Johnson's shares outstanding have been steadily increasing over the years, reaching 4.27 billion shares by the end of 2022.

The company's strong financial performance has led to a steady increase in its stock price, making it an attractive investment opportunity for many investors.

Johnson and Johnson's pharmaceutical segment has been a major driver of the company's growth, with the development of new treatments and vaccines for various diseases.

The company's commitment to innovation and research and development has helped it stay ahead of the competition in the pharmaceutical industry.